Compared with first-line immunotherapy or chemotherapy alone, combination chemoimmunotherapy for advanced/metastatic non–small cell lung cancer has significantly higher antineoplastic drug and associated medical costs.
John Hartman, PhD
Advertisement
Articles by John Hartman, PhD
Advertisement
Latest Updated Articles
- Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non–Small Cell Lung Cancer
Published: May 18th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Energy Insecurity Linked to Higher Depression, Anxiety in US Adults
2
Patients, Providers Strongly Favor Oral Therapies in Psoriasis
3
Misinformation and Knowledge Gaps Undermine Vaccine Protection: Kristina Crothers, MD
4
FDA Expands Sotatercept Indication for PAH
5
